Drug profile

The FDA adverse-event record for Glucosamine + Chondroitin + Fatty Acids + Vitamins

16 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Glucosamine + Chondroitin + Fatty Acids + Vitamins. See the species affected, top reactions, and outcomes below.

16
adverse-event reports
12.5%
death-coded share
Dog
most-reported species
7
Emesis - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
16
Total Reports
2
Deaths Reported
12.5%
Death Rate

Active Ingredients

Glucosamine + Chondroitin + Fatty Acids + Vitamins

Administration Routes

OralUnknown

Species Affected

Dog 16

Most Affected Breeds

Boxer (German Boxer) 2
Retriever - Labrador 2
Bulldog 1
Chihuahua 1
Dachshund - Standard Long-haired 1
Dachshund - Standard Smooth-haired 1
Siberian Husky 1
Corgi (unspecified) 1
Maltese 1
Bichon Frise 1

Most Reported Reactions

Emesis 7
Decreased appetite 2
Diarrhoea 2
Lethargy (see also Central nervous system depression in 'Neurological') 2
Hyperphosphataemia 2
Vomiting 2
Itching 1
Pruritus 1
Diabetes 1
Weight loss 1
INEFFECTIVE, HEARTWORM LARVAE 1
Panting 1

Outcome Breakdown

Recovered/Normal
11 (68.8%)
Recovered with Sequela
2 (12.5%)
Ongoing
1 (6.3%)
Euthanized
1 (6.3%)
Died
1 (6.3%)

Glucosamine + Chondroitin + Fatty Acids + Vitamins Adverse Event Insights

16 reports name Glucosamine + Chondroitin + Fatty Acids + Vitamins; 2 recorded a death outcome (12.5% of reported events, not a population-level mortality rate). Active ingredient: Glucosamine + Chondroitin + Fatty Acids + Vitamins. Administration routes: Oral, Unknown.

By species: Dog (16 reports). By breed: Boxer (German Boxer) (2), Retriever - Labrador (2), Bulldog (1).

Leading clinical signs: Emesis (7), Decreased appetite (2), Diarrhoea (2), Lethargy (see also Central nervous system depression in 'Neurological') (2). Outcome, 16 coded reports: Recovered/Normal leads at 68.8%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.